Literature DB >> 4345098

Chemotherapy of ovarian cancer. New approaches to treatment.

J P Smith, F Rutledge, J T Wharton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4345098     DOI： 10.1002/1097-0142(197212)30:6<1565::aid-cncr2820300623>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  11 in total

Review 1.  Chemotherapy in the management of ovarian carcinoma: a review.

Authors:  J S Malpas
Journal:  J R Soc Med       Date:  1979-05       Impact factor: 5.344

2.  Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.

Authors:  J Mattern; M Kaufmann; H Hinderer; K Wayss; M Volm
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1975

3.  Aspects of treatment of more advanced cases of ovarian cancer.

Authors:  C N Hudson; P P Dendy
Journal:  Proc R Soc Med       Date:  1974-08

Review 4.  Treatment of ovarian cancer: the state of the art.

Authors:  N Einhorn
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 5.  Update in cancer chemotherapy: genitourinary tract cancer, Part 5: Ovarian cancer.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-05       Impact factor: 1.798

6.  Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma.

Authors:  B W Davis; A Goldhirsch; G W Locher; E Dreher; R Greiner; K Burki; K W Brunner
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

7.  Prospective study with HEXA-CAF combination in ovarian carcinoma.

Authors:  G De Palo; R Demicheli; P Valagussa; M De Lena; E Villa
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft.

Authors:  J N Rich; G B Elion; D Wellner; O M Colvin; D R Groothuis; J H Hilton; K E Schlageter; D D Bigner; O W Griffith; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine.

Authors:  R H Earhart; J D Khandekar; D Faraggi; R A Schinella; T E Davis
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

Review 10.  Achievements of cancer chemotherapy.

Authors:  J S Tobias; J M Whitehouse
Journal:  J R Coll Physicians Lond       Date:  1976-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.